<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234870</url>
  </required_header>
  <id_info>
    <org_study_id>CR1_STU00006013</org_study_id>
    <secondary_id>ASCA-9J02</secondary_id>
    <nct_id>NCT01234870</nct_id>
  </id_info>
  <brief_title>Comprehensive Evaluation of Ischemic Heart Disease Using MRI</brief_title>
  <official_title>Comprehensive Evaluation of Ischemic Heart Disease Using MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the diagnostic performance of fully automated motion
      corrected (MC) first pass myocardial perfusion MRI, compared to the original non-corrected
      first pass myocardial perfusion images in a cohort of patients with suspected ischemic heart
      disease, using coronary angiography as the reference standard. It is expected that this
      improved comprehensive protocol for cardiac MRI be accurate at detecting significant coronary
      artery disease and may obviate the need for other more expensive and invasive diagnostic
      tests currently used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary heart disease is the leading cause of death and disability in the US, accounting for
      about one-third of all deaths in subjects over age 35.

      With the development of newer Magnetic Resonance Imaging (MRI) techniques, such as faster
      pulse sequences and parallel imaging, cardiac MRI has become a routine tool for the
      evaluation and detection of myocardial ischemic disease. First pass myocardial perfusion
      (FPMP) using MRI is increasingly being used to assess ischemic heart disease. MRI offers the
      advantages of spatial resolution sufficient to differentiate between subendocardial and
      subepicardial perfusion; shorter examination time and also lack of ionizing radiation. Left
      ventricle cine gradient echo imaging can be used to assess regional ventricular function.
      Left ventricular myocardial viability can also be easily assessed at the same time in order
      to determine the amount of viable left ventricular myocardium and the percentage of
      irreversibly scarred myocardium by delayed enhanced images. Viability imaging is usually
      added to the perfusion protocol to increase specificity by allowing detection of fixed
      perfusion defects, which represent scar. The ultimate cardiac MRI protocol would be to
      combine both of these imaging strategies with a reliable and accurate coronary Magnetic
      Resonance Angiography(MRA) technique, such that obstructive coronary artery disease could be
      evaluated comprehensively at the same time. If all of these techniques can be combined
      together in a single study, it may be feasible to finally achieve a &quot;one stop shop&quot; for
      cardiac Magnetic Resonance Imaging.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnetic Resonance Image Quality Rating</measure>
    <time_frame>Cross sectional study; magnetic resonance images were obtained on all patients using two different acquisition methods.</time_frame>
    <description>The purpose of the study is to assess the incremental value of diagnostic performance using a fully-automated, motion-corrected (MC) first pass myocardial perfusion image acquisition protocol compared to images obtained under a non-corrected, breath-hold, shallow-breathing first pass myocardial perfusion image acquisition protocol in patients with suspected ischemic heart disease. The MR images resulting from two different image acquisition techniques, including Non-Corrected Breath-Hold Shallow-Breathing and Motion-Corrected, were assessed independently by two radiologists (average of 7 years of experience in reading cardiac MRI) using the American Heart Association modified 16 segment model and were evaluated using a four point Likert scale (1 = poor, 2 = fair, 3 = good, and 4 = excellent) for image quality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events to Demonstrate Feasibility of a Comprehensive Cardiac Magnetic Resonance Imaging Protocol</measure>
    <time_frame>14 days</time_frame>
    <description>Adverse events relating to administration of adenosine during a coronary heart disease comprehensive cardiac MRI study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Heart Disease, Ischemic</condition>
  <condition>Atherosclerosis, Coronary</condition>
  <arm_group>
    <arm_group_label>Ischemic heart disease patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with suspected ischemic heart disease prospectively recruited for first pass myocardial perfusion MRI. All subject to receive Gadolinium infusion of 0.075 mmol/kg at rate of 4 ml/sec. Adenosine administered at a rate of 0.14 mg/kg/min for a duration of 4 minutes to induce stress.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadolinium</intervention_name>
    <arm_group_label>Ischemic heart disease patients</arm_group_label>
    <other_name>Magnevist, Bayer HealthCare Pharmaceuticals</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine</intervention_name>
    <arm_group_label>Ischemic heart disease patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Under an Institutional Committee on Human Research board approved protocol 80 patients with
        a suspected myocardial ischemic disease recruited from the cardiac cath laboratory will be
        recruited in this prospective study. Volunteers will be recruited for the purpose of
        protocol development and will not be included in analysis. All subjects will be screened
        for glomerular filtration rate (GFR) within 24 hours before the exam. All patients must
        have a GFR &gt; 30 mL/min/1.73m2 to be part of the study.

        All subjects will be selected following the Nephrogenic Systemic Fibrosis (NSF) guidelines.
        All dialysis patients or end-stage renal disease patients with a creatinine clearance of &lt;
        30 mL/min will not be selected for the study to avoid NSF. Patients with GFR &lt; 60 ml/min
        but &gt;30 ml/min will receive a reduced dose of Gadolinium contrast (0.1 ml/kg).

        Exclusion Criteria:

          1. Age &lt;18 years;

          2. Known contraindication to MR imaging (such as pacemaker placement, magnetic implants,
             etc);

          3. Claustrophobia;

          4. Inability to perform an adequate breath-hold for imaging,

          5. Inability to provide informed consent;

          6. all subjects will be will be screened for GFR within 24 hours before the exam and
             subjects presenting with GFR &lt; 30 ml/min will be excluded;

          7. Pregnant and lactating women;

          8. Patients with hypersensitivity to gadolinium contrast agents, metoprolol, adenosine,
             or nitroglycerin;

          9. Contra indication for Adenosine

               1. 2nd- or 3rd-degree atrioventricular block (except in patients with a functioning
                  artificial pacemaker)

               2. Sinus node disease (except in patients with a functioning artificial

                  pacemaker)

               3. Unstable angina

               4. Acute myocardial infarction

               5. Known or suspected bronchoconstrictive or bronchospastic lung

                  disease (e.g., asthma)

               6. Hypersensitivity to adenosine

               7. Caffeine within 12-24 hours

               8. Theophylline and Dipyridamole products within 24 hours.

         10. Contra indication for Metoprolol

               1. sinus bradycardia

               2. heart block greater than first degree

               3. Cardiac Failure

               4. Bronchospastic Disease

         11. Contra indication for Nitroglycerin

               1. Early myocardial infarction, severe anemia, increased intracranial pressure, and
                  those with a known hypersensitivity to nitroglycerin.

        b .Administration of Nitrostat (nitroglycerin tablets, USP) is contraindicated in patients
        who are using ViagraÂ® since Viagra has been shown to potentiate the hypotensive effects of
        organic nitrates.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C Carr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <results_first_submitted>September 2, 2014</results_first_submitted>
  <results_first_submitted_qc>September 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2014</results_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>James Carr</investigator_full_name>
    <investigator_title>Director of Cardiovascular Imaging, Department of Radiology,Associate Professor of Radiology and Medicine, Northwestern University Feinberg School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Myocardial Perfusion Imaging</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ischemic Heart Disease Patients</title>
          <description>Patients with suspected ischemic heart disease prospectively recruited for first pass myocardial perfusion MRI. All subject to receive Gadolinium infusion of 0.075 mmol/kg at rate of 4 ml/sec. Adenosine administered at a rate of 0.14 mg/kg/min for a duration of 4 minutes to induce stress.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All 40 patients were successfully scanned per the imaging protocol and all images collected were of diagnostic quality and successfully processed. Age, gender, race, ethnicity and BMI were collected on all 40 patients and all have been included in the analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>Adenosine</title>
          <description>Adenosine (Adenoscan) will be infused intravenously at a dose of 0.14mg/kg/min for a total of 4 mins.
adenosine: Adenosine will be infused intravenously at a dose of 0.14mg/kg/min for a total of 4 mins</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.9" spread="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.57" spread="5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Magnetic Resonance Image Quality Rating</title>
        <description>The purpose of the study is to assess the incremental value of diagnostic performance using a fully-automated, motion-corrected (MC) first pass myocardial perfusion image acquisition protocol compared to images obtained under a non-corrected, breath-hold, shallow-breathing first pass myocardial perfusion image acquisition protocol in patients with suspected ischemic heart disease. The MR images resulting from two different image acquisition techniques, including Non-Corrected Breath-Hold Shallow-Breathing and Motion-Corrected, were assessed independently by two radiologists (average of 7 years of experience in reading cardiac MRI) using the American Heart Association modified 16 segment model and were evaluated using a four point Likert scale (1 = poor, 2 = fair, 3 = good, and 4 = excellent) for image quality</description>
        <time_frame>Cross sectional study; magnetic resonance images were obtained on all patients using two different acquisition methods.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ischemic Heart Disease Patients</title>
            <description>Patients with suspected ischemic heart disease prospectively recruited for first pass myocardial perfusion MRI. All subject to receive Gadolinium infusion of 0.075 mmol/kg at rate of 4 ml/sec. Adenosine administered at a rate of 0.14 mg/kg/min for a duration of 4 minutes to induce stress.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnetic Resonance Image Quality Rating</title>
          <description>The purpose of the study is to assess the incremental value of diagnostic performance using a fully-automated, motion-corrected (MC) first pass myocardial perfusion image acquisition protocol compared to images obtained under a non-corrected, breath-hold, shallow-breathing first pass myocardial perfusion image acquisition protocol in patients with suspected ischemic heart disease. The MR images resulting from two different image acquisition techniques, including Non-Corrected Breath-Hold Shallow-Breathing and Motion-Corrected, were assessed independently by two radiologists (average of 7 years of experience in reading cardiac MRI) using the American Heart Association modified 16 segment model and were evaluated using a four point Likert scale (1 = poor, 2 = fair, 3 = good, and 4 = excellent) for image quality</description>
          <units>units on a likert scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Motion Corrected Images</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Corrected Breath-Hold, Shallow-Breathing Image</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The MR images resulting from two different image acquisition techniques, including Non-Corrected Breath-Hold Shallow-Breathing and Motion-Corrected, were assessed independently by two radiologists (average of 7 years of experience in reading cardiac MRI) using the American Heart Association modified 16 segment model and were evaluated using a four point Likert scale (1 = poor, 2 = fair, 3 = good, and 4 = excellent) for image quality</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events to Demonstrate Feasibility of a Comprehensive Cardiac Magnetic Resonance Imaging Protocol</title>
        <description>Adverse events relating to administration of adenosine during a coronary heart disease comprehensive cardiac MRI study.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adenosine</title>
            <description>Adenosine (Adenoscan) will be infused intravenously at a dose of 0.14mg/kg/min for a total of 4 mins.
adenosine: Adenosine will be infused intravenously at a dose of 0.14mg/kg/min for a total of 4 mins</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events to Demonstrate Feasibility of a Comprehensive Cardiac Magnetic Resonance Imaging Protocol</title>
          <description>Adverse events relating to administration of adenosine during a coronary heart disease comprehensive cardiac MRI study.</description>
          <units>occurances of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were monitored for adverse events for 14 days following administration of adenosine.</time_frame>
      <desc>Patients were monitored for adverse events on the day of the MR scan. Following administration of adenosine for stress testing, patients were monitored until fifteen minutes after patient vitals returned to baseline. Following the day of participation, patients were monitored for any serious adverse experiences for 14 days.</desc>
      <group_list>
        <group group_id="E1">
          <title>Adenosine</title>
          <description>Adenosine (Adenoscan) will be infused intravenously at a dose of 0.14mg/kg/min for a total of 4 mins.
adenosine: Adenosine will be infused intravenously at a dose of 0.14mg/kg/min for a total of 4 mins</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The small number of subjects results in reduced statistical power; The cohort was selected from patients at a single medical center, potentially reducing generalizability; Variability in patient behavior during MR scans may affect analyses</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. James Carr</name_or_title>
      <organization>Northwestern University</organization>
      <phone>(312)695-4218</phone>
      <email>jcarr@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

